TAC to the Future. Plus: GSK’s Rapt Deal, Codifying MFN — a BioCentury Podcast

Why It Matters

The deal accelerates GSK’s entry into fast‑growing allergy markets while TAC advances broaden drug‑target space, and policy changes may tighten pricing pressures across biopharma.

Key Takeaways

• TACs broaden targetable protein classes beyond degraders
• GSK pays $2.2 B for Rapt’s allergy platform
• MFN pricing policy now codified in US law
• Priority‑review vouchers face stricter eligibility rules
• J.P. Morgan conference highlights valuation gaps in biotech

Pulse Analysis

The emergence of targeting chimeras (TACs) marks a pivotal evolution in the induced‑proximity field. While PROTACs have demonstrated the feasibility of protein degradation, TACs extend the concept to recruitment, stabilization, and functional modulation of a wider array of proteins. This diversification enables drug developers to tackle previously “undruggable” targets such as transcription factors and scaffolding proteins, potentially unlocking new therapeutic classes in oncology, immunology, and metabolic disease. Investors are watching the early‑stage data closely, as successful TAC candidates could command premium valuations similar to the first wave of PROTAC successes.

GSK’s $2.2 billion acquisition of Rapt Therapeutics underscores the strategic value of niche biotech assets that bring geographic and scientific diversification. Rapt’s allergy platform, originally sourced from a Chinese biotech partner in 2024, offers a pipeline of biologics and small molecules that complement GSK’s existing respiratory and immunology portfolio. The transaction reflects a broader industry trend where large pharma firms use cash‑rich balance sheets to secure innovative pipelines, mitigate R&D risk, and gain footholds in emerging markets. For Rapt, the deal provides scale, regulatory expertise, and global commercialization capabilities that could accelerate product launches.

Policy developments in Washington add another layer of complexity to the commercial landscape. The codification of the "most‑favored‑nation" (MFN) drug‑pricing rule creates a uniform ceiling for price negotiations, potentially compressing margins for high‑priced biologics and specialty drugs. Simultaneously, reforms to priority‑review vouchers aim to limit their proliferation, affecting timelines for breakthrough therapies. An increased NIH budget, however, promises more grant funding and collaborative opportunities, especially for early‑stage technologies like TACs. Together, these dynamics force biopharma executives to balance innovative pipeline investments with disciplined pricing strategies, a theme echoed in the J.P. Morgan Healthcare Conference takeaways where valuation gaps between innovators and legacy players were a focal point.